Kura Oncology Inc Cash Flow Conversion Efficiency
Kura Oncology Inc cash flow conversion efficiency. Based on the latest financial reports, Kura Oncology Inc (KURA) has a cash flow conversion efficiency ratio of -1.292x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-62.55 Million) by net assets ($48.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Kura Oncology Inc (2009–2025)
Cash flow conversion efficiency of Kura Oncology Inc from 2009 to 2025. This chart illustrates how Kura Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Kura Oncology Inc for real-time trading data and today's change.
Kura Oncology Inc Cash Flow Conversion Ratio Explained
Kura Oncology Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Kura Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kura Oncology Inc ranked by their cash flow conversion efficiency. Also see market cap of Kura Oncology Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
0.034x |
|
Jaya Real Property Tbk
JK:JRPT
|
0.026x |
|
IPERIONX LTD SP.ADR/10
F:30Z0
|
N/A |
|
Tetra Technologies Inc
NYSE:TTI
|
-0.042x |
|
Wuhan Fingu Electronic Technology Co Ltd
SHE:002194
|
0.036x |
|
Janux Therapeutics Inc
NASDAQ:JANX
|
-0.013x |
|
MasterBrand Inc.
NYSE:MBC
|
0.065x |
|
Jiangsu Seagull Cooling Tower
SHG:603269
|
0.235x |
Annual Cash Flow Conversion Efficiency for Kura Oncology Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Kura Oncology Inc from 2009 to 2025. Review how much free cash does Kura Oncology Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $174.13 Million | $-64.06 Million | -0.368x | -213.29% |
| 2024-12-31 | $413.64 Million | $134.32 Million | 0.325x | +203.35% |
| 2023-12-31 | $397.27 Million | $-124.82 Million | -0.314x | -19.98% |
| 2022-12-31 | $420.28 Million | $-110.06 Million | -0.262x | -26.90% |
| 2021-12-31 | $506.61 Million | $-104.55 Million | -0.206x | -80.55% |
| 2020-12-31 | $610.90 Million | $-69.83 Million | -0.114x | +54.33% |
| 2019-12-31 | $218.78 Million | $-54.76 Million | -0.250x | +17.18% |
| 2018-12-31 | $160.99 Million | $-48.66 Million | -0.302x | +15.13% |
| 2017-12-31 | $79.86 Million | $-28.44 Million | -0.356x | +20.10% |
| 2016-12-31 | $56.88 Million | $-25.35 Million | -0.446x | -104.14% |
| 2015-12-31 | $82.10 Million | $-17.93 Million | -0.218x | -29526.93% |
| 2014-12-31 | $-3.43 Million | $-2.55K | 0.001x | -99.62% |
| 2013-12-31 | $-123.96K | $-24.42K | 0.197x | -17.18% |
| 2012-12-31 | $-95.35K | $-22.68K | 0.238x | -15.92% |
| 2011-12-31 | $-68.03K | $-19.24K | 0.283x | -39.75% |
| 2010-12-31 | $-40.99K | $-19.24K | 0.469x | -59.14% |
| 2009-12-31 | $-18.60K | $-21.37K | 1.149x | -- |
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapi… Read more